NEW YORK, July 31, 2025 /PRNewswire/ -- Genpact (NYSE: G), an advanced technology services and solutions company, today announced that Thimaya Subaiya has been appointed to the Company's Board of Directors, effective immediately. Thimaya Subaiya "Thimaya brings proven expertise in scaling services and software businesses through the right balance of innovation, simplicity, and operational excellence," said Balkrishan "BK" Kalra, President and CEO, Genpact. "His experience directly supports our GenpactN ...

Core Insights - Broadway Financial Corporation reported a consolidated net income before preferred dividends of $603 thousand for Q2 2025, an increase from $269 thousand in Q2 2024, but a net loss attributable to common stockholders of $147 thousand in Q2 2025 compared to a net income of $269 thousand in Q2 2024 [1][2][4] Financial Performance - For the first six months of 2025, the company reported a consolidated net loss before preferred dividends of $1.3 million, a decline from a net income of $105 thousand in the same period of 2024 [2][11] - Net interest income before provision for credit losses for Q2 2025 was $7.8 million, a decrease of 2.1% from $7.9 million in Q2 2024, primarily due to a $1.3 million decrease in interest income [5][6] - The net interest margin increased to 2.63% in Q2 2025 from 2.41% in Q2 2024, driven by an increase in the average rate earned on interest-earning assets [5][9] Expense Management - Non-interest expense for Q2 2025 was $7.5 million, an increase of 3.3% from $7.3 million in Q2 2024, mainly due to higher professional services and operational losses [8][11] - The company achieved a reduction in non-interest expenses by 26.23% or $2.7 million since the last quarter, largely due to the operational loss from a fraudulent wire [4][11] Asset Quality and Capital - The allowance for credit losses increased to $8.6 million as of June 30, 2025, compared to $8.1 million at the end of 2024, with non-accrual loans at 0.42% of total loans [8][16] - Total assets decreased by $76.3 million to $1.227 billion as of June 30, 2025, reflecting decreases in cash, securities, and net loans [16][19] - Stockholders' equity was $285.5 million, representing 23.3% of total assets, with a Community Bank Leverage Ratio of 15.69% [16][19] Deposits and Borrowings - Total deposits increased by $53.5 million, or 7.2%, to $798.9 million as of June 30, 2025, attributed to an increase in certificates of deposit [9][16] - Total borrowings decreased significantly by $126.3 million to $69.2 million as of June 30, 2025, improving the cost of funds [9][16]

THE WOODLANDS, Texas, July 31, 2025 /PRNewswire/ -- Huntsman Corporation (NYSE: HUN) announced today that its Board of Directors has declared a $0.25 per share cash dividend on its common stock. The dividend is payable on September 30, 2025, to stockholders of record as of September 15, 2025.About Huntsman:Huntsman Corporation is a publicly traded global manufacturer and marketer of differentiated and specialty chemicals with 2024 revenues of approximately $6 billion. Our chemical products number in the tho ...

MECHANICSBURG, Pa., July 31, 2025 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its second quarter ended June 30, 2025, and the declaration of a cash dividend.For the second quarter ended June 30, 2025, revenue increased 4.5% to $1,339.6 million, compared to $1,281.7 million for the same quarter, prior year. Income from continuing operations before other income and expense increased 17.2% to $86.5 million for the second q ...

NEW YORK, July 31, 2025 /PRNewswire/ -- Neuberger Berman Real Estate Securities Income Fund Inc. (NYSE American: NRO) (the "Fund") has announced a distribution declaration of $0.0312 per share of common stock. The distribution announced today is payable on August 29, 2025, has a record date of August 15, 2025, and has an ex-date of August 15, 2025.Under its level distribution policy, the Fund anticipates that it will make regular monthly distributions, subject to market conditions, of $0.0312 per share of c ...

NEW YORK, July 31, 2025 /PRNewswire/ -- Neuberger Berman Next Generation Connectivity Fund Inc. (NYSE: NBXG) (the "Fund") has announced a distribution declaration of $0.10 per share of common stock. The distribution announced today is payable on August 29, 2025, has a record date of August 15, 2025, and has an ex-date of August 15, 2025.Under its level distribution policy, the Fund anticipates that it will make regular monthly distributions, subject to market conditions, of $0.10 per share of common stock, ...

Q2'25 net sales of $483.4 million, an increase of 4% Y/Y Organic sales volumes increased 2% Y/Y driven by new business wins of approximately 5% Q2'25 net loss of $66.6 million and loss per diluted share of $3.78, which includes an $88.8 million impairment charge Q2'25 non-GAAP net income of $30.0 million and non-GAAP earnings per diluted share of $1.71 Delivered adjusted EBITDA and adjusted EBITDA margins of $75.5 million and 15.6%, respectively, in Q2'25 Share repurchases totaled $32.7 million in Q2'25 an ...

Core Viewpoint - Novartis has received FDA approval for an updated label for Leqvio® (inclisiran), allowing its use as a monotherapy to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, alongside diet and exercise [1][2][3] Group 1: Product Information - Leqvio is now indicated for use as a standalone treatment, removing the previous requirement for combination with statin therapy [3] - The updated label specifies "hypercholesterolemia" instead of "primary hyperlipidemia," focusing on LDL-C reduction [3] - Leqvio is administered twice a year by healthcare providers, which may enhance patient adherence and long-term management of LDL-C levels [2][8] Group 2: Market Need and Impact - Up to 80% of patients with atherosclerotic cardiovascular disease (ASCVD) in the US do not achieve the recommended LDL-C target of less than 70 mg/dL, highlighting a significant unmet medical need [2][8] - The 2025 ACC/AHA guidelines recommend more aggressive treatment strategies to meet LDL-C targets, further emphasizing the importance of Leqvio's new indication [2][8] Group 3: Company Background - Novartis has global rights to develop, manufacture, and commercialize Leqvio through a collaboration with Alnylam Pharmaceuticals, a leader in RNAi therapeutics [4] - The company aims to address critical challenges in cardiovascular disease management and improve patient outcomes through innovative treatments [10][11]

NORTHVILLE, Mich., July 31, 2025 /PRNewswire/ -- Cooper-Standard Holdings Inc. (NYSE: CPS) today reported results for the second quarter 2025.Second Quarter 2025 Highlights Gross profit of $93.1 million, an increase of 12.2% vs. the second quarter of 2024 Operating income of $37.3 million, an increase of 234.5% vs. the second quarter of 2024 Net loss of $1.4 million, or $(0.08) per diluted share, an improvement of $74.8 million vs. the second quarter of 2024 Adjusted net income of $1.0 million, or $0.06 per ...

PHILADELPHIA, July 31, 2025 /PRNewswire/ -- FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced it has received registration for Fundatis® herbicide powered by Isoflex® active in Great Britain for use in winter wheat and winter barley. Isoflex® active is a novel herbicide when used in cereals and is classified by the Herbicide Resistance Action Committee (HRAC) as a Group 13 herbicide. Fundatis® herbicide provides growers with a new tool to help manage herbicide resi ...